Trials / Completed

CompletedNCT02854046

Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome

Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome : a Multicentric, Retrospective Cohort

Status: Completed
Phase: —
Study type: Observational
Enrollment: 80 (actual)

Sponsor: Nantes University Hospital · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

Calciphylaxis, also called Calcific Uremic Arteriolopathy (CUA) is a lethal affection mostly affecting patient in end stage renal disease. The survival rate is described around 20 to 46% at one year. Clinical presentation is very painful skin lesions with ulceration mostly located on the trunk or thigh. Current knowledge about physiopathology, diagnostic practice and therapeutic is very limited. Actually there is no European study about calciphylaxis and risk factors, diagnostic practice and outcome factors.

Conditions

Calciphylaxis

Interventions

Type	Name	Description
OTHER	Calcific Uremic Arteriolopathy

Timeline

Start date: 2016-07-01
Primary completion: 2016-10-31
Completion: 2016-10-31
First posted: 2016-08-03
Last updated: 2021-09-21

Source: ClinicalTrials.gov record NCT02854046. Inclusion in this directory is not an endorsement.